阿托伐他汀减少冠脉介入治疗引起心肌损伤及炎性反应的临床观察

目的 探讨经皮冠状动脉介入治疗(PCI)前预防性给予阿托伐他汀能否减轻PCI相关炎症反应及心肌损伤.方法 78例拟行PCI的不稳定型心绞痛患者随机分为阿托伐他汀预治疗组(42例)和对照组(36例).治疗组在PCI前接受7 d的阿托伐他汀40 mg/d治疗;对照组在PCI前不使用他汀类药物.两组患者均接受其他常规治疗,且...

Observation of atorvastatin in the reduction of myocardial injury and inflammatory response during percutaneous coronary intervention

Objective To investigate of atorvastatin in the reduction of myocardial injury and inflammatory response during the percutaneous coronary intervention （PCI） by pre-treatment. Methods 78 patients scheduled for PCI for unstable angina were randomly assigned to atorvastatin pre-treatment group （42 cases） and control group （36 cases）. The treatment group received atorvastatin 40 mg/d for 7 days before PCI treatment, the control group before PCI did not use statins. All patients received other conventional treatments, and accepted statin thera- py in the post-PCI. High sensitivity C-reactive protein （hs-CRP）, myeloperoxidase （MPO）, cardiac troponin I （cTnI） was tested in 24 h before and after surgery, and record the incidence of myocardial infarction in the perioperative. Results The hs-CRP, MPO, cTnI after surgery in the treatment group and the control group increased significantly compared with preoperative （t=8.2707, 3.5621, 2.6705 and 3.1671, 3.8826, 2.4049, P〈0.01 or P〈 0.05 ）. The hs-CRP, MPO, cTnl of preoperative and postoperative in the treatment group was significantly lower than control group （t=3.3525, 2.1587, 2.8529 and 3.1171, 2.7133, 2.0915, P〈0.01 or P〈0.05）. The incidence of myocardial infarction of the treatment group in the perioperative was significantly lower than the control group （X2=4.3858, P〈0.05 ）. Conclusion It can significantly reduce the inflammation caused by PCI and myocardial injury that given atorvastatin 40 mg/d 7 days preventive treatment before PCI, and it is security.